The detectability of mycobacteria in culture by the use of nonisotopic, chemiluminescent DNA probes for Mycobacterium tuberculosis and the M. avium-M. intracellulare complex (MAC) was evaluated and compared with that by the use of 125I-labeled DNA probes for the same mycobacteria. In the assay, rRNA-directed DNA probes labeled with acridinium ester (AE-DNA probes) were used. Unhybridized probes were chemically degraded, and the esterified acridinium on the hybridized probes was hydrolyzed by the addition of alkaline hydrogen peroxide solution, resulting in the production of visible light which was measured with a luminometer.
Infections caused by Mycobacterium tuberculosis are found worldwide (16) , and those caused by M. tuberculosis and the M. avium-M. intracellulare complex (MAC) associated with AIDS have recently been found to be increasing (11) . Therefore, infections caused by these mycobacteria have become a major clinical problem (6, 7) . Rapid and accurate identification and discrimination between M. tuberculosis and MAC are important, since the treatment of each infection is significantly different (1, 14) .
Conventional approaches to the laboratory diagnosis of infections caused by these organisms are based on acid-fast stains and the recovery of organisms from cultured clinical specimens; this is followed by a variety of tests. However, acid-fast stains cannot distinguish M. tuberculosis from MAC or other mycobacteria, and they are not sensitive enough in most instances. In addition, culture and biochemical testing require more than 6 to 8 weeks. Because of these disadvantages inherent in the conventional methods, several techniques, such as the use of 125I-labeled DNA probes (Gen-Probe, Inc., San Diego, Calif.) (3, 10) and the BACTEC system (Becton Dikinson, Inc., Towson, Md.) (15) , have been developed and are commercially available. However, both methods require radioisotope facilities, resulting in the limitation of their practical use in many clinical laboratories.
Acridinium-ester-labeled DNA (AE-DNA) probes have been made available as an alternative to DNA probes labeled with 125I (5). By using AE-DNA probes, a new detection system, the so-called hybridization protection assay (2) , which is based on the selective chemical degradation of acridinium on unhybridized probes, has been developed and has been applied to the use of AE-DNA probes for M. '251-labeled DNA probe. The commercial Gen-Probe Rapid Diagnostic systems for M. tuberculosis, M. avium, and M. intracellulare were used according to the instructions of the manufacturer. This separation assay consists of the following four steps: (i) sample preparation, (ii) hybridization with the 1251I-labeled probes, (iii) separation of unhybridized probes with hydroxyapatite, and (iv) measurement of radioactivity. Statistical analysis. All assays were performed in duplicate. The statistical parameters of sensitivity and specificity were calculated by standard methods (12) .
RESULTS
The accuracy of the detection system with the AE-DNA probes was evaluated by testing various strains of the different types of mycobacteria ( Table 1 ). The average RLUs for strains of the M. tuberculosis complex obtained by using the M. tuberculosis probe were over 100 times higher than those for any mycobacteria other than the M. tuberculosis complex (4 x 105 versus 3 x 103 RLUs). The average RLUs for strains of MAC obtained by using the MAC probe were 100 times higher than those for the M. tuberculosis complex and non-MAC strains (3 x 105 versus 3 x 103 RLUs). These results indicated the good discriminatory power of the assay system with the AE-DNA probes. Accordingly, it would be reasonable to define the cutoff value of the assay as 3 x 104 RLUs; a specimen was considered positive if a luminescence of greater than 3 x 104 RLUs was obtained.
The detection limits of the assay obtained with AE-DNA probes were compared with those obtained with the 125-DNA probes by using serial 10-fold dilutions of six isolates of cultured mycobacteria (two isolates each of M. tuberculosis, M. avium, and M. intracellulare). As shown in Fig. 1, the results of the two methods correlated very closely. The cutoff value for the assay with 125I-labeled DNA probes was previously defined as 10% hybridization, which was equivalent to a detectability of 106 CFU of bacteria per reaction tube (3) . In good agreement with this, the detectability in the assay with the AE-DNA probe was also 106 CFU per reaction tube if the cutoff value of 3 x 10' RLUs was used.
A total of 107 clinical isolates of mycobacteria (47 M. tuberculosis, 27 M. avium, 9 M. intracellulare, and 24 atypical non-MAC mycobacteria) identified by the conventional method were tested with the AE-DNA probes. These results were then compared with those of the conventional method and the assay with 1251I-labeled DNA probes ( Table   2 (9), it might be identified as M. avium. On the basis of the results of the detection limits, sensitivity, and specificity, the nonisotopic AE-DNA probes proved to have the same accuracy as the 1251-labeled DNA probes.
DISCUSSION
The results of this study showed that the AE-DNA probes for M. tuberculosis and MAC can be used as a rapid and reliable diagnostic method in the clinical laboratory. Compared with 1251I-labeled DNA probes, nonisotopic probes had almost the same sensitivities, specificities, and detection limits. There are several assay formats for DNA probes. Commercially available DNA probes for M. tuberculosis, M. avium, and M. intracellulare are labeled with 1251, which is hazardous to laboratory workers. Since washing steps are required to separate the hybridized and unhybridized probes in the assay, a large amount of isotopic waste must be kept while its radioactivity decays. Furthermore, the 125I-labeled probe has a shelf life of only 1 month. In contrast to these limitations, the nonisotopic probe is safe and has a considerably longer shelf life; the AE-DNA probe can be stored for over 1 year if it is refrigerated. An acridinium ester has already been used to label the DNA probe for Neisseria gonorrhoeae (the prototype Gen-Probe PACE system) (5). However, in that assay, magnetic particles that specifically bind to hybridized probes are used, and washing must be repeated three times to remove unhybridized probes. In contrast, a new method, the so-called hybridization protection assay, was applied in the system described here. This method is based on the selective chemical degradation of the acridinium ester label so that the acridinium ester associated with the unhybridized probe is rapidly lost, whereas the acridinium ester associated with the hybridized probe is protected. Then, the chemiluminescence emitted by the acridinium ester released from the hybridized probe is measured (2) . Thus, all the reactions are carried out in one tube and washing steps are not required. This one-step homogeneous format is one of the main advantages of the AE-DNA probe, and this makes it potentially automatable. Furthermore, all the procedures can be completed within 1 h.
The AE-DNA probe for MAC is a mixture of both the AE-DNA probe for M. avium and that for M. intracellulare. Using the 125I-labeled probes which can distinguish M. avium from M. intracellulare, Saito et al. (13) reported a very interesting epidemiological study in which they elucidated the distributions of M. avium and M. intracellulare in various districts of Japan. However, in a clinical sense, the combined probe would be more convenient because differentiation of MAC isolates into M. avium and M. intracellulare is not necessary for determining optimal therapy.
Although the detection limits of this system are almost the same as those of the radioisotope probes, they are still not sensitive enough to directly detect mycobacterial rRNA in clinical specimens. There are several rRNA-directed DNA probes for other organisms. In some of them, such as those for Legionella spp. (4) , N. gonorrhoeae (5), and Chlamydia trachomatis (8) , organisms can be detected directly in clinical specimens by the DNA probes. The detection limits of the AE-DNA probes for mycobacteria achieved in this study were at the level of 106 CFU. One can increase the apparent detectability by lowering the cutoff value for the AE-DNA probes, but this will result in an increase in false-positive results. Therefore, to get reliable results, it is recommended that clinical specimens be cultured before they are tested with the AE-DNA probes used in this study. If a method could be developed to lyse the cell wall of the mycobacterium more efficiently, mycobacteria would be directly detectable by the DNA probe in clinical specimens.
In summary, the new method to detect M. tuberculosis and MAC with the AE-DNA probe is simple, rapid, and reliable and is a very practical diagnostic tool that can be used in any clinical laboratory.
